Company: WFC-PC
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000072971-25-000090
Chunk: 64

Company: WELLS FARGO & COMPANY/MN
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 64
---
         |        |     |         |         |     |         |           |           |            |
|                         |     | 6/25/2024  |                            |           |        |     |                          |     |           |     |         |        |     |         |         |     | 284,834 |           |           | 16,292,505 |
| Bridget E. Engle        |     |            |                            | 2,100,000 |        |     |                          |     |           |     |         |        |     |         |         |     |         |           |           |            |
|                         |     | 10/22/2024 |                            |           |        |     |                          |     |           |     |         |        |     |         |         |     | 288,899 |           |           | 18,723,544 |
|                         |     | 12/10/2024 |                            |           |        |     |                          |     |           |     |         |        |     |         |         |     |   7,796 |           |           |    561,702 |

1. Equity grants are awarded as part of the annual incentive compensation process and as part of employment offers for new hires. Grants made as part of the annual incentive compensation process are generally awarded in January after fourth quarter earnings are released.

2. The amount shown in column (c) for each individual is based on the individual’s target total variable compensation for the year and the maximum percentage of the target that is payable in non-equity for 2024 as follows: 25% for the CEO and 30% for the other NEOs. The balance of each individual’s target total variable compensation is payable in equity. Information regarding the target total variable compensation for each NEO is provided in the CD&A.

3. The potential equity incentive plan awards shown in columns (e) and (f) represent the target and maximum number of PSAs granted during 2024, with the maximum value described in footnote (4) of the 202 4 Summary Compensation Table and target value included in column (e) of the 202 4 Summary Compensation Table . Additional information regarding the terms of these awards appears in the narrative following this table and in our CD&A. Mr. Rivas and Ms. Engle joined the Company in 2024 and were not granted PSAs during the calendar year.

#### 2025 Proxy Statement